USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Nov 2, 2022 | Sep 2022 | - | - | $0.07 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Nov 2, 2022 | Sep 2022 | - | - | $5.00M |
Bellicum Pharmaceuticals, Inc's next earnings date is Wednesday, Nov 2, 2022 for the fiscal quarter ending Sep 2022.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 0 | $0.00 | $0.00 | $0.00 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2022 | 0 / 0 | $-2.93 | $-2.93 | $-2.93 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 1 | $0.00 | $0.00 | $0.00 |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Aug 10, 2022 | Jun 2022 | $-0.69 | - | - |
| May 12, 2022 | Mar 2022 | $-0.67 | $-0.25 | 62.69% |
| Mar 24, 2022 | Dec 2021 | $-0.40 | $0.11 | 127.50% |
| Nov 4, 2021 | Sep 2021 | - | $0.07 | - |
| Aug 12, 2021 | Jun 2021 | $-0.85 | $-0.22 | 74.12% |
| May 14, 2021 | Mar 2021 | $-1.37 | $-1.12 | 18.25% |
| Mar 30, 2021 | Dec 2020 | $-1.06 | $0.98 | 192.45% |
| Nov 5, 2020 | Sep 2020 | $-3.15 | $-0.18 | 94.28% |
| Aug 6, 2020 | Jun 2020 | $-2.87 | $-8.55 | -197.91% |
| May 7, 2020 | Mar 2020 | $-2.73 | $1.09 | 139.93% |
| Mar 12, 2020 | Dec 2019 | $-4.34 | $-5.82 | -34.26% |
| Nov 6, 2019 | Sep 2019 | $-5.30 | $-6.80 | -28.30% |
| Aug 5, 2019 | Jun 2019 | $-5.40 | $-5.80 | -7.41% |
| May 7, 2019 | Mar 2019 | $-5.82 | $-5.50 | 5.50% |
| Mar 12, 2019 | Dec 2018 | $-6.46 | $-6.30 | 2.48% |
| Nov 6, 2018 | Sep 2018 | $-5.68 | $-5.50 | 3.08% |
| Aug 7, 2018 | Jun 2018 | $-5.63 | $-6.00 | -6.67% |
| May 8, 2018 | Mar 2018 | $-7.04 | $-6.80 | 3.45% |
| Mar 13, 2018 | Dec 2017 | $-6.97 | $-6.60 | 5.33% |
| Nov 7, 2017 | Sep 2017 | $-7.40 | $-7.10 | 4.05% |
| Aug 8, 2017 | Jun 2017 | $-6.63 | $-7.40 | -11.64% |
| May 8, 2017 | Mar 2017 | $-7.04 | $-8.00 | -13.68% |
| Mar 13, 2017 | Dec 2016 | $-7.33 | $-7.40 | -0.97% |
| Nov 9, 2016 | Sep 2016 | $-6.34 | $-6.60 | -4.10% |
| Aug 8, 2016 | Jun 2016 | $-5.80 | $-6.10 | -5.17% |
| May 9, 2016 | Mar 2016 | $-5.10 | $-5.60 | -9.80% |
| Mar 14, 2016 | Dec 2015 | $-4.20 | $-6.30 | -50.00% |
| Nov 9, 2015 | Sep 2015 | $-0.38 | $-0.51 | -34.21% |
| Aug 13, 2015 | Jun 2015 | $-0.49 | $-0.40 | 18.37% |
| May 11, 2015 | Mar 2015 | $-0.30 | $-0.30 | - |
| Mar 11, 2015 | Dec 2014 | $-0.37 | $-2.02 | -445.95% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 24, 2022 | Dec 2021 | $0.00 | $-1.16 | - |
| Mar 30, 2021 | Dec 2020 | $-8.70 | $-6.66 | - |
| Mar 12, 2020 | Dec 2019 | $-22.17 | $-23.92 | - |
| Mar 12, 2019 | Dec 2018 | $-2.37 | $-24.60 | - |
| Mar 13, 2018 | Dec 2017 | $-2.94 | $-29.10 | - |
| Mar 13, 2017 | Dec 2016 | - | $-25.70 | - |
| Mar 14, 2016 | Dec 2015 | - | $-7.51 | - |
| Mar 11, 2015 | Dec 2014 | - | $-2.02 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Aug 10, 2022 | Jun 2022 | - | - | - |
| May 12, 2022 | Mar 2022 | - | $0.00 | - |
| Mar 24, 2022 | Dec 2021 | $250.00K | $-5.69M | - |
| Nov 4, 2021 | Sep 2021 | $250.00K | $5.00M | 20.00% |
| Aug 12, 2021 | Jun 2021 | $250.00K | $700.00K | 2.80% |
| May 14, 2021 | Mar 2021 | $250.00K | $0.00 | - |
| Mar 30, 2021 | Dec 2020 | $250.00K | $500.00K | 2.00% |
| Nov 5, 2020 | Sep 2020 | $250.00K | $0.00 | - |
| Aug 6, 2020 | Jun 2020 | $900.00K | $0.00 | - |
| May 7, 2020 | Mar 2020 | $400.00K | $5.13M | 12.83% |
| Mar 12, 2020 | Dec 2019 | $630.00K | $5.13M | 8.15% |
| Nov 6, 2019 | Sep 2019 | $1.20M | $103.00K | 0.09% |
| Aug 5, 2019 | Jun 2019 | $750.00K | $1.39M | 1.85% |
| May 7, 2019 | Mar 2019 | $650.00K | $516.00K | 0.79% |
| Mar 12, 2019 | Dec 2018 | $1.19M | $312.00K | 0.26% |
| Nov 6, 2018 | Sep 2018 | $110.00K | $292.00K | 2.65% |
| Aug 7, 2018 | Jun 2018 | $70.00K | $362.00K | 5.17% |
| May 8, 2018 | Mar 2018 | $30.00K | $154.00K | 5.13% |
| Mar 13, 2018 | Dec 2017 | $980.00K | $-69.00K | - |
| Nov 7, 2017 | Sep 2017 | $30.00K | $126.00K | 4.20% |
| Aug 8, 2017 | Jun 2017 | $80.00K | $128.00K | 1.60% |
| May 8, 2017 | Mar 2017 | - | $128.00K | - |
| Mar 13, 2017 | Dec 2016 | - | $81.00K | - |
| Nov 9, 2016 | Sep 2016 | - | $114.00K | - |
| Aug 8, 2016 | Jun 2016 | - | $101.00K | - |
| May 9, 2016 | Mar 2016 | - | $92.00K | - |
| Mar 14, 2016 | Dec 2015 | - | $34.00K | - |
| Nov 9, 2015 | Sep 2015 | - | $57.00K | - |
| Aug 13, 2015 | Jun 2015 | - | $84.00K | - |
| May 11, 2015 | Mar 2015 | - | $107.00K | - |
| Mar 11, 2015 | Dec 2014 | - | $15.00K | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 24, 2022 | Dec 2021 | $0.00 | $6.20K | - |
| Mar 30, 2021 | Dec 2020 | $0.00 | $500.00 | - |
| Mar 12, 2020 | Dec 2019 | $2.48M | $7.14M | 188.02% |
| Mar 12, 2019 | Dec 2018 | $1.97M | $1.12M | -43.15% |
| Mar 13, 2018 | Dec 2017 | $1.12M | $185.00K | -83.48% |
| Mar 13, 2017 | Dec 2016 | - | $388.00K | - |
| Mar 14, 2016 | Dec 2015 | - | $282.00K | - |
| Mar 11, 2015 | Dec 2014 | - | $1.78M | - |
BLCM's next earnings date is Wednesday, Nov 2, 2022 for the fiscal quarter ending Sep 30, 2022.
Bellicum Pharmaceuticals, Inc's previous earnings date was Aug 10, 2022 for its fiscal quarter ended Jun 30, 2022.
Bellicum Pharmaceuticals, Inc's previous annual earnings date was Mar 24, 2022 for its fiscal year ended Dec 31, 2021.
BLCM's earnings per share (EPS) was $-1.16, missing the consensus analysts forecast of $0.00 by % , and higher than the previous year's EPS (Dec 2020) by -82.58%.
Revenues were $6.20K.
The company reported a net income of $-9.71K.
Bellicum Pharmaceuticals, Inc reported a free cash flow of $-22.21K for its fiscal year, compared to $-55.38M a year ago.
